Skip to main content

Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease.

Cel

Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around €15.8bn. This chronic non-communicable disease is increasing at an alarming rate due to increasing European obesity, alcohol use and ageing. The three main causes of the disease; alcohol, fatty liver and viral hepatitis are amenable to prevention and treatment. Gut-derived endotoxins and bacterial translocation are central factors implicated in the pathogenesis of fatty liver disease and, the development and progression of cirrhosis. In cirrhosis, current state-of-the-art therapy to prevent recurrent complications of advanced cirrhosis is to use poorly absorbed antibiotics but long-term antibiotic therapy has problems associated with bacterial resistance, infection with resistant organisms and the cost. Treatment of fatty liver and modulation of bacterial translocation in early cirrhosis to prevent complications is an unmet need. Our academic-industrial consortium has developed a novel, patented, safe and cheap nanoporous carbon that modulates the effects of bacterial translocation in animal models of liver disease. Our feasibility studies demonstrate that this product advances the current state-of-the-art, is a TRL 4/5 and is now ready for validation through clinical trials. We propose to investigate the safety and efficacy of this novel nanoporous carbon in patients with fatty liver disease and cirrhosis. If successful, we will be able to confirm an innovative, cost-effective and novel strategy for the management of this chronic disease in a European population. Exploitation of the results of the CARBALIVE project will support the continued development of this carbon through additional private and public sector investment. The use of this innovative therapy is expected to reduce the economic burden of the disease in Europe, allow patients to achieve enhanced quality of life, improve survival, and allow many patients to return to economic productivity.

Zaproszenie do składania wniosków

H2020-PHC-2014-two-stage
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

RIA - Research and Innovation action

Koordynator

UNIVERSITY COLLEGE LONDON
Adres
Gower Street
WC1E 6BT London
United Kingdom
Rodzaj działalności
Higher or Secondary Education Establishments
Wkład UE
€ 1 826 222,81

Uczestnicy (14)

MAST CARBON INTERNATIONAL LTD

Zakończenie uczestnictwa

United Kingdom
Wkład UE
€ 398 495,13
Adres
Jays Close Viables
RG22 4BA Basingstoke
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ALPHA BIORESEARCH, SL
Hiszpania
Wkład UE
€ 598 250
Adres
Calle Lopez De Hoyos 155 3 Puerta 6 7
28002 Madrid
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITY OF BRIGHTON
United Kingdom
Wkład UE
€ 178 750
Adres
Lewes Road Mithras House
BN2 4AT Brighton
Rodzaj działalności
Higher or Secondary Education Establishments
A2F ASSOCIATES LIMITED
United Kingdom
Wkład UE
€ 137 500
Adres
7 Laureate Paddocks
CB8 0AP Newmarket
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Hiszpania
Wkład UE
€ 93 750
Adres
Calle Rossello 149 Puerta Bjs
08036 Barcelona
Rodzaj działalności
Other
UNIVERSITA DEGLI STUDI DI PADOVA

Zakończenie uczestnictwa

Włochy
Wkład UE
€ 51 351,69
Adres
Via 8 Febbraio 2
35122 Padova
Rodzaj działalności
Higher or Secondary Education Establishments
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
Hiszpania
Wkład UE
€ 93 750
Adres
Passeig Vall D Hebron 119-129 Edificio De Recerca
08035 Barcelona
Rodzaj działalności
Research Organisations
ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA
Włochy
Wkład UE
€ 93 750
Adres
Via Zamboni 33
40126 Bologna
Rodzaj działalności
Higher or Secondary Education Establishments
FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA
Portugalia
Wkład UE
€ 76 000
Adres
Avenida Professor Egas Moniz, Edificio Hospital Santa Maria
1649-028 Lisboa
Rodzaj działalności
Higher or Secondary Education Establishments
SERVICIO MADRILENO DE SALUD
Hiszpania
Wkład UE
€ 93 750
Adres
Plaza Carlos Trias Bertran 7
28020 Madrid
Rodzaj działalności
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
UNIVERSITAET BERN
Szwajcaria
Wkład UE
€ 0
Adres
Hochschulstrasse 6
3012 Bern
Rodzaj działalności
Higher or Secondary Education Establishments
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
Francja
Wkład UE
€ 18 277,19
Adres
3 Avenue Victoria
75000 Paris
Rodzaj działalności
Research Organisations
YAQRIT LIMITED
United Kingdom
Wkład UE
€ 2 170 732,93
Adres
The Network Building 97 Tottenham Court Road
W1T 4TP London
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)
Hiszpania
Wkład UE
€ 82 500
Adres
Travessera De Gracia 11, 7Th Floor
08021 Barcelona
Rodzaj działalności
Research Organisations